

Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024



Prof. Gianantonio Rosti
IRCCS Istituto Romagnolo per lo
Studio dei Tumori (IRST) "Dino Amadori",
Meldola, Italy



Dr Carla Boquimpani
Fundação Saúde,
Rio de Janeiro, Brazil



Prof. Dr. med. Susanne Saussele
University of Mannheim,
Mannheim, Germany

Recorded following EHA 2024 Hybrid Congress, Madrid, Spain, 13–16 June
and ESH-iCMLf 2024, Prague, Czech Republic, 27–29 September

Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities*
- *touchIME accepts no responsibility for errors or omissions*



What do the latest efficacy data for TKIs tell us about the evolving treatment paradigm for patients with CML in the first line?

Prof. Gianantonio Rosti
IRCCS Istituto Romagnolo per
lo Studio dei Tumori (IRST)
"Dino Amadori", Meldola, Italy



Recorded following EHA 2024 Hybrid Congress, Madrid, Spain, 13–16 June
and ESH-iCMLf 2024, Prague, Czech Republic, 27–29 September

The approval of TKI treatment in CML has changed the fate of many patients with the disease



CML, chronic myeloid leukaemia; EMA, European Medicines Agency; TKI, tyrosine kinase inhibitor.


1. Vener C, et al. *Blood Adv.* 2020;4:2723–35; 2. Tesileanu CMS, et al. *Oncologist.* 2023;28:628–32; 3. Dhillon S. *Drugs.* 2022;82:469–75;

4. Jabbour E, Kantarjian H. *Am J Hematol.* 2020;95:691–709; 5. Yeung DT, et al. *Blood.* 2022;139:3474–9.

S103: Asciminib provides superior efficacy and excellent safety and tolerability vs TKIs in newly diagnosed CML in the pivotal ASC4FIRST study

Hochhaus A, et al.

Patients with MMR at week 48 (%)



Safety and tolerability

Adverse events, %	Asciminib (n=200)	Imatinib (n=99)	2G TKIs (n=102)
Grade ≥3	38.0	44.4	54.9
Leading to discontinuation	4.5	11.1	9.8
Leading to dose adjustment/interruption	30.0	39.4	52.9

Asciminib demonstrated superior efficacy vs imatinib and 2G TKIs and acceptable safety and tolerability in patients with newly diagnosed CML



*Estimated using the Mantel-Haenszel method after stratifying for prerandomization-selected TKI and baseline ELTS risk groups (both IRT data). Adjusted 1-sided p value calculated based on the graphical gatekeeping procedure. The null hypothesis is rejected if the adjusted p value is ≤0.025. †All IS-TKIs: Imatinib (n=102) + 2G-TKI (n=102; nilotinib, 48%; dasatinib, 41%; bosutinib, 11%). 2G, second generation; CI, confidence interval; CML, chronic myeloid leukaemia; ELTS, European Treatment and Outcome Study long-term survival score; IRT, interactive response technology; IS, investigator-selected; MMR, major molecular response; TKI, tyrosine kinase inhibitor. Hochhaus A, et al. Presented at: EHA 2024 Hybrid Congress, Madrid, Spain. 13–16 June 2024. Oral presentation S103.

P730: Asciminib as initial therapy with addition of lower dose TKIs for patients with CML who do not achieve a deep molecular remission (ALERTCML)


Atallah E, et al.

Patients achieving a molecular response (N=36)*

Median follow-up: 24 weeks



Adverse events occurring ≥10 times



Asciminib as first-line therapy is effective and well tolerated


*MR2, BCR::ABL ≤1%; MR3, BCR::ABL ≤0.1%; MR4, BCR::ABL ≤0.01%; MR5, BCR::ABL ≤0.001%. CML, chronic myeloid leukaemia; CPK, creatine phosphokinase; MR, molecular response; WBC, white blood cell. Atallah E, et al. Presented at: EHA 2024 Hybrid Congress, Madrid, Spain. 13–16 June 2024. Poster presentation P730.

P718: Results of ponatinib as frontline therapy for CML in chronic phase

Haddad F, et al.

Patients achieving a response over time (N=51)

Median time on therapy: 13 months



Safety*



16%

CV SAEs:
Eight, in six patients



16%

Dose reduction due to CV AEs:
Eight patients



10%

Permanent discontinuations due to CV AEs:
Five patients

In newly diagnosed CML-CP, ponatinib was associated with high rates of cytogenetic and molecular responses. However, CV toxicity posed a challenge for its use in the first-line setting

*59% of patients (n=30) had ≥ 1 CV comorbidity at baseline. AE, adverse event; CCyR, complete cytogenetic response; CML, chronic myeloid leukaemia; CP, chronic phase; CV, cardiovascular; MMR, major molecular response; MR, molecular response; MR4.0, BCR::ABL $\leq 0.01\%$; MR4.5, BCR::ABL $\leq 0.0032\%$; SAE, serious AE. Haddad F, et al. Presented at: EHA 2024 Hybrid Congress, Madrid, Spain. 13–16 June 2024. Poster presentation P718.

What do the latest efficacy data for TKIs tell us about the evolving treatment paradigm for patients with CML in the second- and later-line settings?

Prof. Gianantonio Rosti
IRCCS Istituto Romagnolo per
lo Studio dei Tumori (IRST)
"Dino Amadori", Meldola, Italy




Recorded following EHA 2024 Hybrid Congress, Madrid, Spain, 13–16 June
and ESH-iCMLf 2024, Prague, Czech Republic, 27–29 September

S173: Outcomes with ponatinib in patients with chronic-phase chronic myeloid leukemia and the *T315I* mutation: 4-year results from the OPTIC trial

Apperley J, et al.

Efficacy in patients with the *T315I* mutation (N=67)

Median follow-up 60.6–63.5 months¹



Safety and tolerability, according to starting dose²

Adverse events, %	15 mg (n=21)	30 mg (n=21)	45 mg (n=25)
Grade ≥ 3 TEAE	38	38	60
TEAEs leading to discontinuation	5	14	8
TE-AOE	5	14	8
Exposure-adjusted TE-AOE	2.8	7.3	2.4

Ponatinib demonstrated long-term efficacy and manageable safety. A ponatinib 45 mg starting dose with reduction to 15 mg upon attainment of $\leq 1\%$ BCR::ABL1S provided the optimal benefit:risk ratio





P719: Lower-dose initiating bosutinib is safe and effective for resistant or intolerant to prior therapy CML patients (BOGI trial): A single-arm, multicenter, phase II trial

Kimura S, et al.

Bosutinib discontinuation rate at 12 months

Selected safety data

■ This study: 200 mg starting dose (n=35)¹ ■ Previous study: 500 mg starting dose (n=28)²



The lower initiating bosutinib dose reduced the drug discontinuation rate due to severe DRTs, especially diarrhoea, while maintaining clinical efficacy

CML, chronic myeloid leukaemia; DRT, drug-related toxicities.


1. Kimura S, et al. Presented at: EHA 2024 Hybrid Congress, Madrid, Spain. 13–16 June 2024. Poster presentation P719; 2. Nakaseko C, et al. *Int J Hematol.* 2015;101:154–64.

S172: Improved tolerability with dasatinib 5 days compared to 7 days per week in patients with CML in chronic phase. Final results of the DasaHIT trial

La Rosée P, et al.

Molecular efficacy (MMR) at 24 months

■ Experimental arm (100 mg QD, 5 days + 2 days rest)
■ Standard arm (100 mg QD, 7 days)



Safety

Median cTS=2



for both the experimental and standard arms

Pleural- and pericardial effusions occurred **significantly less frequently** in the experimental arm vs the standard arm:
8.0% vs 16.2% (p=0.0468)

There was a favourable effect of dose modification of dasatinib to reduce pleural/cardiac effusions while maintaining efficacy in patients with CML in the first-line; patients in the later line seemed to derive more benefit from continuous dosing

ESH-iCMLf oral presentation: Propensity-score matching analysis comparing treatment outcomes of asciminib with ponatinib in later line treatment for chronic myeloid leukemia patients

Kim D, et al.




At 1 year in overall cohort: Improved EFS with asciminib in patients with no T315I mutation ($p=0.0002$) *but not* in those with T315I-mutated disease ($p=0.575$)

Asciminib had at least equal efficacy to ponatinib, provided there was no asciminib-resistant ABL1 KD mutation. Asciminib was associated with a superior event-free and failure-free survival rate vs ponatinib overall, and in the PSMA-selected subgroup

P722: Olverembatinib overcomes ponatinib and asciminib resistance in patients with heavily pretreated CML and Philadelphia+ ALL


Jabbour E, et al.

Response to olverembatinib according to treatment history



Median follow-up: 48.9 weeks

Safety (N=80)



Olverembatinib was efficacious and well tolerated at doses up to 50 mg QOD in pts with heavily pretreated CML-CP and advanced leukaemia, including ponatinib- or asciminib-resistant/intolerant disease

AE, adverse event; ALL, acute lymphoblastic leukaemia; CCyR, complete cytogenetic response; CML, chronic myeloid leukaemia; CP, chronic phase; MMR, major molecular response; QOD, every other day; SAE, serious AE; TRAE, treatment-related AE.

Jabbour E, et al. Presented at: EHA 2024 Hybrid Congress, Madrid, Spain. 13–16 June 2024. Poster presentation P722.

How might the emerging data for current and investigational TKIs for CML influence the treatment of patients now and in the future?

Prof. Gianantonio Rosti
IRCCS Istituto Romagnolo per
lo Studio dei Tumori (IRST)
"Dino Amadori", Meldola, Italy



Recorded following EHA 2024 Hybrid Congress, Madrid, Spain, 13–16 June
and ESH-iCMLf 2024, Prague, Czech Republic, 27–29 September

P712: Update of the French Stop Imatinib Study (STIM1) extended long-term follow-up

Mahon F, et al.

Durability of disease remission following imatinib discontinuation (N=100)

Median molecular follow-up after imatinib discontinuation

153 months
(range 9–180)

None had CML progression

Confirmed molecular recurrence

62%

Molecular recurrence-free survival at 120 months

37%
(95% CI 28–48)

Molecular recurrence-free survival at 156 months

35%
(95% CI 26–46)

Overall survival

10 years

97% (95% CI 94–100)

20 years

88% (95% CI 81–96)

Results contribute significantly to understanding treatment-free remission in CML and its long-term survival implications


P721: Clinical efficacy of first-line nilotinib or imatinib therapy in patients with CML – nationwide real-life data

Belohlavkova P, et al.

Comparison of TKI efficacy in matched treatment groups

Patients treated with nilotinib achieved **CCyR** and **MMR** faster than imatinib-treated matched patients (both $p < 0.001$)

No difference in **disease-specific survival** between matched groups or all four groups, due to older age and comorbidities in imatinib-unmatched groups




In this real-world analysis with long-term follow-up, first-line nilotinib demonstrated faster achievement of CCyR and MMR, and a higher FFS and EFS, but did not show any benefit for OS. Imatinib is still an effective choice for first-line treatment of CML-CP, especially for older patients with comorbidities

ESH-iCMLf oral presentation: Asciminib provides long-term, durable molecular responses and a consistent safety profile in patients with T315I-mutated CML-CP with up to approximately 6 years' exposure: final analysis from a phase 1 trial
Cortes J, et al.

Cumulative MMR over time with asciminib 200 mg BID (n=45)

Median exposure, 3.5 years



Safety*

Adverse events (%)	All patients (N=48)
All grade	100
Grade ≥3	60
Leading to dose adj./ interrupt.	44
Leading to discontinuation	10
Requiring additional therapy	81
Deaths	6
Arterial occlusive events, All/Gr ≥3	12.5 ⁺ /6.3

This final analysis confirms asciminib as a treatment option in T315I-mutated CML-CP, with potential to provide durable MMR regardless of prior ponatinib treatment status, with sustained efficacy and tolerability

*After 1.4 years' added exposure compared with the previous data cutoff (2.1 years of median exposure), the rate of grade ≥3 AEs (60.4%) did not increase, and no new AEs leading to discontinuation occurred. Rates of AEs of special interest were consistent with the previous analysis. ⁺Most (5 of 6) patients had prior exposure to ≥3 TKIs and all had ≥1 past or active cardiovascular risk factor at baseline. No arterial occlusive events led to dose adjustment/interruption/discontinuation. Adj./interrupt., adjustment or interruption; AE, adverse event; BID, twice daily; CML-CP, chronic-phase chronic myeloid leukaemia; Gr, grade, MMR, major molecular response. Cortes J, et al. Presented at: ESH-iCMLf 2024, Prague, Czech Republic, 27–29 September. Oral presentation.

ESH-iCMLf oral presentation: Investigation of resistance mechanisms of the allosteric BCR::ABL1 inhibitor asciminib

Leske IB, et al.

 To investigate the structural basis and molecular mechanisms of asciminib-resistant mutations

Hypothesis: The mechanism of action of asciminib-resistant mutations differs with their location on BCR::ABL1

Design:

- Analysis of BCR::ABL1 mutations from asciminib-treated patients
- Structural analysis of four clusters:
 1. Vicinity of myristoyl pocket
 2. KD, ATP-binding pocket
 3. Kinase N-lobe (top)
 4. SH3-domain/SH2-KD-linker
- Pure, homogeneous Abl protein produced in *E. coli* to study asciminib binding/resistance

ESH-iCMLf oral presentation: Investigation of resistance mechanisms of the allosteric BCR::ABL1 inhibitor asciminib

Leske IB, et al.

	Mutation (Location)				
	None (Wild-type)	A337T/G463D (myristoyl pocket)	M244V (KD, N-lobe)	F359I (KD, C-lobe/ATP)	Y115N (SH3 domain)
Abl construct	Binding/ K_D (nM)				
KD only	4.4	151/360	3.0	4.3	--
SH2-KD	3.5	287/101	40.0	14.7	--
SH3-SH2-KD	5.3	178/93	10.8	6.3	6.1

Two mechanisms of asciminib resistance?

Mutations with *strongly decreased* binding affinity: **myristoyl pocket mutations**

Mutations with *unchanged* binding affinity: **outside of myristoyl pocket**, but still confer medium-to-strong resistance in cells

ESHi-CMLf oral presentation: Investigation of resistance mechanisms of the allosteric BCR::ABL1 inhibitor asciminib

Leske IB, et al.

Molecular mechanisms of asciminib resistance, by point mutation:

A337V/T, G463D:
Sterically block asciminib binding

M244V, Y115N:
Allosterically shift BCR::ABL1 to its active conformation, that cannot reassemble

F359V/I:
Induce a more active conformation of KD that is overactive, although assembled

Rational actions for therapeutic decisions, based on the data

Switch to ATP-competitive TKI; myristoyl-pocket mutations are ATP-competitive TKI sensitive

Dose escalation, or switch to ATP-competitive TKI

Dose escalation or potential combination
Do not switch to nilotinib or imatinib; F359 mutation is resistant to these agents


Asciminib resistance is more diverse than ATP-competitive TKI resistance
The asciminib resistance mechanism is complex, e.g. resistance despite unaltered binding affinity

S174: A phase 2, randomized trial of ruxolitinib in addition to BCR::ABL1 TKIs in CML patients with molecular evidence of disease (SWOG TRIAL S1712)


Sweet K, et al.

Molecular response at 12 months (N=75)

Median time on TKI prior to enrolment: 3.2 years



Grade 3 related AEs



The combination of ruxolitinib plus TKIs warrants further investigation in a larger study to determine if it could lead to higher treatment-free remission rates

ESH iCMLf oral presentation: Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML

Lang F, et al.

TEAEs in phase Ia

Median (range) duration of exposure 20 weeks (0.1–80)

Preferred term, n (%)		All patients (N=37)	
		Any grade	Grade 3/4
Haematologic	Neutropenia [†]	4 (10.8)	4 (10.8)
	Thrombocytopenia [‡]	4 (10.8)	2 (5.4)
	Leukopenia [§]	1 (2.7)	0
	Pancytopenia	1 (2.7)	1 (2.7)
	Anaemia	2 (5.4)	0
Non-haematologic*	Headache	5 (13.5)	0
	Lipase increased	5 (13.5)	0
	Arthralgia	4 (10.8)	0
	Diarrhoea	4 (10.8)	0
	Nausea	4 (10.8)	0

Cumulative MMR[¶] in patients without T315I mutation

At 24 weeks

	MMR, % (n/N)
All evaluable patients	44.4 (8/18)
Achieved MMR	23.1 (3/13)
Maintained MMR	100 (5/5)
TKI-resistant	41.7 (5/12)
TKI-intolerant	50 (3/6)
Post-asciminib	40 (4/10)

ELVN-001 had a low incidence of AEs, consistent with a selective kinase profile, with no exposure–toxicity relationship identified to date. There was early evidence of anti-CML activity, including in those who received prior asciminib

*Non-haematologic TEAEs in ≥10% of patients. [†]Grouped term for neutropenia includes neutrophil count decreased. [‡]Grouped term for thrombocytopenia includes platelet count decreased.

[§]Grouped term for leukopenia includes white blood cell count decreased. [¶]Molecular response was assessed by central qPCR measured every 4 weeks x6, then every 12 weeks. MMR is

defined as BCR::ABL1 <0.1%. AE, adverse event; CML, chronic myeloid leukaemia, MMR, major molecular response; qPCR, quantitative polymerase chain reaction;

TEAE, treatment-emergent AE. Lang F, et al. Presented at: ESH-iCMLf 2024, Prague, Czech Republic, 27–29 September. Oral presentation.